A Novel Transcatheter Device to Treat Calcific Aortic Valve Stenosis: An Ex Vivo Study

Overview

Journal Cardiovasc Eng Technol

Publisher Springer

Date 2025 Feb 5

PMID 39909987

Authors

Francesca Perico

Eleonora Salurso

Fabio Pappalardo

Michal Jaworek

Enrico Fermi

Maria Chiara Palmieri

Flavius Constantin Apostu

Riccardo Vismara

Marco Vola

Affiliations

Soon will be listed here.

Abstract

Purpose: Aortic valve stenosis (AVS) is the most common valvular disease in developed countries. Surgical or transcatheter bioprosthetic aortic valve (AV) replacement is the standard treatment for severe AVS. However, bioprostheses are prone to structural degeneration. Hence, in terms of lifetime management, there is a need for therapies that can postpone AV replacement. With the aim of fragmenting calcifications and restoring AV leaflets flexibility, a new transcatheter debridement device (TDD) exploiting ultrasound is under development. We performed an ex-vivo study on human hearts to quantify how TDD treatment affects stenotic AVs hemodynamic. Additionally, a qualitative histological analysis was performed to assess TDD's impact on AV leaflets.

Methods: Three human hearts affected by AVS were characterized pre- and post-treatment in an ex-vivo beating heart simulator. To replicate physiological flowrates, a pulsatile pump was connected to the left ventricle, while a systemic impedance simulator connected to the aortic root and a reservoir connected to the left atrium closed the hydraulic circuit. Transvalvular pressure drop (ΔPsys), backflow volume, and effective orifice area (EOA) were evaluated. For histological analysis, AV leaflets sections were stained with Haematoxylin/Eosin and AlizarineRedS to highlight calcifications.

Results: The treatment induced a reduction in ΔPsys in all tested samples, improving EOA, but caused an increase in backflow volume. Moreover, histology suggested AV leaflets integrity.

Conclusions: The TDD procedure improved AV fluid-dynamics during systole in all tested samples, without evidence of damage to tissues. This suggests TDD could be a promising option to postpone AV replacement for patients with AVS.

References

Rodriguez-Gabella T, Voisine P, Puri R, Pibarot P, Rodes-Cabau J . Aortic Bioprosthetic Valve Durability: Incidence, Mechanisms, Predictors, and Management of Surgical and Transcatheter Valve Degeneration. J Am Coll Cardiol. 2017; 70(8):1013-1028. DOI: 10.1016/j.jacc.2017.07.715. View

Leopaldi A, Vismara R, Lemma M, Valerio L, Cervo M, Mangini A . In vitro hemodynamics and valve imaging in passive beating hearts. J Biomech. 2012; 45(7):1133-9. DOI: 10.1016/j.jbiomech.2012.02.007. View

Lanzarone E, Vismara R, Fiore G . A new pulsatile volumetric device with biomorphic valves for the in vitro study of the cardiovascular system. Artif Organs. 2009; 33(12):1048-62. DOI: 10.1111/j.1525-1594.2009.00812.x. View

Dvir D, Bourguignon T, Otto C, Hahn R, Rosenhek R, Webb J . Standardized Definition of Structural Valve Degeneration for Surgical and Transcatheter Bioprosthetic Aortic Valves. Circulation. 2018; 137(4):388-399. DOI: 10.1161/CIRCULATIONAHA.117.030729. View

Pettenazzo E, Deiwick M, Thiene G, Molin G, Glasmacher B, Martignago F . Dynamic in vitro calcification of bioprosthetic porcine valves: evidence of apatite crystallization. J Thorac Cardiovasc Surg. 2001; 121(3):500-9. DOI: 10.1067/mtc.2001.112464. View